Development and characterization of a nano-scale contrast agent

Oeffinger, Brian; Wheatley, Margaret A.

doi:10.1016/j.ultras.2003.11.011

Cited by 166 publications

(113 citation statements)

References 10 publications

Supporting

Mentioning

109

Contrasting

Order By: Relevance

“…Tumor vascular leakiness is the result of increased angiogenesis and the presence of cytokines, bradykinin and other vasoactive factors that enhance permeability [13]. Tumor angiogenesis is characterized by vessels with irregular diameters and branching, and tumors lacking defining structures of vasculature such as arterioles, capillaries, or venules.…”

Section: Passive Targetingmentioning

confidence: 99%

Impact of Nanoparticles on Cancer Therapy

Alkhatib¹,

Albishi²,

Mahassni³

2013

Trop. J. Pharm Res

View full text Add to dashboard Cite

The tremendous contribution of nanotechnology to the treatment and diagnosis of medical diseases has recently attracted the attention of anticancer researchers. Most of the new nanoparticle carriers have improved drug bioavailability and reduced the cytotoxic effects of the drugs. This article presents an overview of the recent advances of nanotechnology in cancer therapy. It covers the mechanisms of cellular uptake for anticancer drugs delivered in nanoscale systems by either active or passive targeting. The various nanoscale systems employed in drug delivery and their immense potential in diagnosis andimaging of cancerous tumors are also addressed.

show abstract

Section: Passive Targetingmentioning

confidence: 99%

Impact of Nanoparticles on Cancer Therapy

Alkhatib¹,

Albishi²,

Mahassni³

2013

Trop. J. Pharm Res

View full text Add to dashboard Cite

show abstract

“…It has been reported that the 200 nm (smaller than 700 nm) NPs could reach the interstitial fluid surrounding the tumor cells through the leaking endothelium of the tumor microvasculature. 31 Coumarin 6 was also loaded into the SNPs as a fluorescence probe to compare the cellular uptake efficiency. It is obvious that incorporating different compositions would affect the nanoparticle size ( while 100% PTX release was not observed from PTX-SNPs and PTX-NPs within 60 hours ( Figure 2).…”

Section: Discussionmentioning

confidence: 99%

Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma

Xiao¹,

Qin²,

Yang³

et al. 2014

IJN

View full text Add to dashboard Cite

Targeted nanoparticle (NP) delivery vehicles are emerging technologies, the full potential of which has yet to be realized. Sulfatide is known to bind to extracellular matrix glycoproteins that are highly expressed in breast tumors. In this study, we report for the first time the combination of sulfatide and lipid perfluorooctylbromide NPs as a targeted breast cancer delivery vehicle for paclitaxel (PTX). PTX-sulfatide-containing lipid perfluorooctylbromide NPs (PTX-SNPs) were prepared using the emulsion/solvent evaporation method. PTX-SNPs exhibited a spherical shape, small particle size, high encapsulation efficiency, and a biphasic release in phosphate-buffered solution. The cytotoxicity study and cell apoptosis assay revealed that blank sulfatide-containing lipid perfluorooctylbromide NPs (SNPs) had no cytotoxicity, whereas PTX-SNPs had greater EMT6 cytotoxicity levels than PTX-lipid perfluorooctylbromide NPs (PTX-NPs) and free PTX. An in vitro cellular uptake study revealed that SNPs can deliver greater amounts of drug with more efficient and immediate access to intracellular targets. In vivo biodistribution measured using high-performance liquid chromatography confirmed that the PTX-SNPs can target breast tumor tissues to increase the accumulation of PTX in these tissues. The in vivo tumor inhibition ability of PTX-SNPs was remarkably higher than PTX-NPs and free PTX. Furthermore, toxicity studies suggested that the blank SNPs had no systemic toxicity. All results suggested that SNPs may serve as efficient PTX delivery vehicles targeting breast carcinoma.

show abstract

“…These SAs increase the ultrasonic cavitation effect by changing the acoustic environment within the tumor thereby boosting energy deposition and enhancing the efficacy and safety of HIFU therapy [16][17][18]. Even so, organic contrast agents have the disadvantages of extremely large particle size and low biostability, which prevent them from permeating tumor tissues [19][20]. Furthermore, microbubbles may impair the focusing of HIFU beam in tissues that can result in damage to prefocal tissues and shielding of the original targeted focus [21].…”

Section: Ivyspringmentioning

confidence: 99%

A Multifunctional Theranostic Nanoagent for Dual-Mode Image-Guided Hifu/Chemo- Synergistic Cancer Therapy

Zhang

Cai

2017

Ultrasound in Medicine & Biology

View full text Add to dashboard Cite

High-intensity focused ultrasound (HIFU) is deemed to be a promising noninvasive therapeutic modality for cancers as well as non-neoplastic diseases. However, the accuracy of the technique in the diagnosis and treatment of tumors remains unsatisfactory. HIFU, when combined with multifunctional synergistic agents (SAs), has the potential to be of greater diagnostic and therapeutic efficacy. Here we describe a smart and multifunctional hollow mesoporous Prussian blue (HMPBs) theranostic nanoplatform, the hollow structure of which is capable of encapsulating doxorubicin (DOX) and perfluorohexane (HMPBs-DOX/PFH). In vitro and in vivo studies validated that HMPBs-DOX/PFH can be used as an amplifiable dual-mode imaging contrast agent, which can simultaneously enhance ultrasound (US) and photoacoustic (PA) imaging for guiding and monitoring tumor therapy. When exposed to HIFU, this versatile HMPBs-DOX/PFH agent could increase the cavitation effect and use lower HIFU intensity to achieve coagulative necrosis. Furthermore, it significantly accelerated the release of DOX thereby enhancing chemotherapeutic efficacy and avoiding systemic side effects of the drug. Such a novel theranostic nanoplatform is expected to integrate dual-mode guided imaging with greater therapeutic efficacy and fewer side effects and is very promising for the noninvasive synergistic tumor therapy.

show abstract

Development and characterization of a nano-scale contrast agent

Cited by 166 publications

References 10 publications

Impact of Nanoparticles on Cancer Therapy

Impact of Nanoparticles on Cancer Therapy

Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma

A Multifunctional Theranostic Nanoagent for Dual-Mode Image-Guided Hifu/Chemo- Synergistic Cancer Therapy

Contact Info

Product

Resources

About